パラジウム酸化添加複合体による医薬品の多様化
Mycah R Uehling1,2, Ryan P King2, Shane W Krska1
1Merck & Co. Inc., Kenilworth, NJ 07033, USA.
まとめ
研究者は,効率的なクロスカップリング反応のための安定したパラジウム酸化添加複合体 (OAC) を開発した. これらのOACは,複雑な分子合成を簡素化し,従来の触媒方法よりも穏やかな条件と高い成功率を提供します.
科学分野:
- 合成有機化学
- 薬剤化学
- 材料科学
背景:
- パラジウム触媒による交互結合反応は 新しい材料や薬の発見に不可欠です
- 交互結合による密度の高い機能を備えた分子の合成は依然として困難である.
- 既存の触媒方法は,しばしば厳しい条件や特定の基板の互換性を要求します.
研究 の 目的:
- 安定したパラジウム複合体を用いたクロスカップリング反応の代替戦略を開発する.
- 伝統的なパラジアム触媒のクロスカップリングに伴う制限を克服するために.
- 複雑な分子合成におけるこの新しいアプローチの広範な有用性を実証する.
主な方法:
- 薬のようなアリルハライドから派生したパラジウム酸化添加複合物 (OAC) の利用されたステキオメトリック量.
- 温和な環境下でのクロスカップリング反応.
- ベンチ上で長時間保存したOACの安定性をテストした.
主要な成果:
- OACを使用したクロスカップリング反応は,一般的に,触媒方法と比較して成功率が高い,穏やかな条件下で進行した.
- OACは,何ヶ月も貯蔵した後に反応性を維持し,驚くべき安定性を示しました.
- ナノモールスケールの自動結合と自然製品の後期派生においてOACを成功裏に適用した.
結論:
- パラジウム酸化添加複合体は,従来のクロスカップリング触媒に強固で効率的な代替品を提供します.
- OACの安定性と反応性は,複雑な薬剤の発見と改変を含む化学合成の新たな可能性を可能にします.
- このアプローチは,機能的な分子の合成を簡素化し,利用可能な化学空間の範囲を広げます.
関連する概念動画
Pharmaceutical Equivalents
201
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
201
Conjugate Addition (1,4-Addition) vs Direct Addition (1,2-Addition)
4.3K
α,β-Unsaturated carbonyl compounds with two electrophilic sites, the carbonyl carbon, and the β carbon, are susceptible to nucleophilic attack via two modes: conjugate or 1,4-addition and direct or 1,2-addition.
Conjugate addition results in a thermodynamically stable product. The reaction retains the stronger C=O bond at the expense of the weaker C=C π bond. The process is slow as the β carbon is less electrophilic than the carbonyl carbon.
Direct addition products are...
Conjugate addition results in a thermodynamically stable product. The reaction retains the stronger C=O bond at the expense of the weaker C=C π bond. The process is slow as the β carbon is less electrophilic than the carbonyl carbon.
Direct addition products are...
4.3K
Pyruvate Oxidation
168.8K
After glycolysis, the charged pyruvate molecules enter the mitochondria via active transport and undergo three enzymatic reactions. These reactions ensure that pyruvate can enter the next metabolic pathway so that energy stored in the pyruvate molecules can be harnessed by the cells.
First, the enzyme pyruvate dehydrogenase removes the carboxyl group from pyruvate and releases it as carbon dioxide. The stripped molecule is then oxidized and releases electrons, which are then picked up by NAD+...
First, the enzyme pyruvate dehydrogenase removes the carboxyl group from pyruvate and releases it as carbon dioxide. The stripped molecule is then oxidized and releases electrons, which are then picked up by NAD+...
168.8K
Oxidation Numbers
42.5K
In redox reactions, the transfer of electrons occurs between reacting species. Electron transfer is described by a hypothetical number called the oxidation number (or oxidation state). It represents the effective charge of an atom or element, which is assigned using a set of rules.
42.5K
Additional Subnuclear Structures
5.4K
The eukaryotic nucleus is a double membrane-bound organelle that contains nearly all of the cell’s genetic material in the form of chromosomes. It is rightly called the “brain” of the cell as it shoulders the responsibility of responding to various physiological processes, stress, altered metabolic conditions, and other cellular signals.
The nucleus contains many membrane-less subnuclear organelles or nuclear bodies, such as nucleoli, Cajal bodies, speckles,...
The nucleus contains many membrane-less subnuclear organelles or nuclear bodies, such as nucleoli, Cajal bodies, speckles,...
5.4K
Additional Subnuclear Structures
2.6K
2.6K


